Brief: Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma
16/07/2024 13:17
July 16 (Reuters) - Lisata Therapeutics Inc LSTA.O :
* LISATA THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN
ITS
PHASE 2A BOLSTER TRIAL OF CERTEPETIDE IN FIRST-LINE
CHOLANGIOCARCINOMA
* LISATA THERAPEUTICS INC - TOP-LINE DATA NOW ANTICIPATED
MID-2025
* LISATA THERAPEUTICS INC: COMPLETE ENROLLMENT ACHIEVED
NEARLY SIX
MONTHS AHEAD OF PLAN
* LISATA THERAPEUTICS INC - ADDITION OF SECOND-LINE
CHOLANGIOCARCINOMA ARM TO BOLSTER TRIAL
Source text for Eikon: ID:nGNXbJrHcL
Further company coverage: LSTA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lisata Therapeutics
See all newsBrief: Lisata Therapeutics - Amends Merger Offer Price To $4 Per Share Plus CVR
Brief: Lisata Therapeutics Enters Into Definitive Agreement To Be Acquired By Kuva Labs, Inc.
U.S. STOCKS ON THE MOVE-Oklo, AMD, Lam Research
U.S. STOCKS ON THE MOVE-Aligos, Intel, Travelers Companies
Lisata jumps as Kuva Labs strikes acquisition deal